Infographics in this collection offer quick and clear visual representations of some of the more complex aspects of cancer, scientific study, and the National Cancer Institute (NCI) as the federal government’s lead agency for cancer research.
Most of these multimedia assets are in the public domain, may be used free of charge for any educational or non-commercial purpose, and cannot be copyrighted. They may not be used to state or imply NCI’s endorsement of any commercial product, service, or activity. Please
credit the source of these products as: The National Cancer Institute.
On This Page
Precision Medicine: Discovering unique therapies that treat an individual’s cancer based on the specific abnormalities of their tumor.
NCI-MATCH precision medicine clinical trial is exploring treating patients based on the molecular profiles of their tumors.
National Clinical Trials Network (NCTN)
Few major changes were made to the Cooperative Group Program since it was first begun in the 1950s. Over the past 5 years, the Institute of Medicine and other expert committees carefully reviewed the Cooperative Group Program and concluded that with 10 decentralized groups (nine adult groups and one pediatric), each with its own operations and statistical centers, tissue banks, and other scientific support services, it needed to become more efficient and collaborative, and restructured to fulfill the promise of precision cancer medicine.
The NCTN structure includes five U.S. Network groups and the Canadian Collaborating Clinical Trials Network. Membership in the individual NCTN groups is based on criteria that are specific to each group. Sites can belong to more than one group, and membership in at least one group allows a site to participate in the trials led by any NCTN group for which their investigators are qualified. Consequently, researchers from the LAPS, NCORP, other academic centers, community practices, and international members associated with the Network groups may all enroll patients onto NCTN trials. Clinical trials led by NCTN groups may receive support from the IROC Group, ITSAs, and tissue banks, according to the scientific needs of the trials.
An illustration describing randomization in the clinical trials process.
Breast Cancer in Women
Determining breast cancer risk: The discovery of
BRCA1 and BRCA2 gene mutations improved screening and treatment decisions for breast and ovarian cancers.